![Biology | Free Full-Text | What Can De Novo Protein Design Bring to the Treatment of Hematological Disorders? Biology | Free Full-Text | What Can De Novo Protein Design Bring to the Treatment of Hematological Disorders?](https://pub.mdpi-res.com/biology/biology-12-00166/article_deploy/html/images/biology-12-00166-g001.png?1675063175)
Biology | Free Full-Text | What Can De Novo Protein Design Bring to the Treatment of Hematological Disorders?
![De novo biosynthesis of rNTPs adapted from Williamson and co-workers... | Download Scientific Diagram De novo biosynthesis of rNTPs adapted from Williamson and co-workers... | Download Scientific Diagram](https://www.researchgate.net/publication/354605947/figure/fig1/AS:1068342785880065@1631724177540/De-novo-biosynthesis-of-rNTPs-adapted-from-Williamson-and-co-workers-27-28-The-four.png)
De novo biosynthesis of rNTPs adapted from Williamson and co-workers... | Download Scientific Diagram
![F-Actin and myosin IIA co-evolution during de novo crypt formation.... | Download Scientific Diagram F-Actin and myosin IIA co-evolution during de novo crypt formation.... | Download Scientific Diagram](https://www.researchgate.net/publication/352577126/figure/fig8/AS:1037370321272834@1624339766539/F-Actin-and-myosin-IIA-co-evolution-during-de-novo-crypt-formation-a-b-Apical-and-basal.jpg)
F-Actin and myosin IIA co-evolution during de novo crypt formation.... | Download Scientific Diagram
![ASH 2022: Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial) ASH 2022: Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)](https://larvolclin.s3.us-west-2.amazonaws.com/1671787549201744399063a5741d40a78.png)
ASH 2022: Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)
![Medical sterilizer - Novo Pro 23L - Ningbo Joident Electronics Technology Co. Ltd - steam / benchtop Medical sterilizer - Novo Pro 23L - Ningbo Joident Electronics Technology Co. Ltd - steam / benchtop](https://img.medicalexpo.com/images_me/photo-g/102862-13203150.jpg)
Medical sterilizer - Novo Pro 23L - Ningbo Joident Electronics Technology Co. Ltd - steam / benchtop
![Co-assembled Nanocarriers of De Novo Thiol-Activated Hydrogen Sulfide Donors with an RGDFF Pentapeptide for Targeted Therapy of Non-Small-Cell Lung Cancer | ACS Applied Materials & Interfaces Co-assembled Nanocarriers of De Novo Thiol-Activated Hydrogen Sulfide Donors with an RGDFF Pentapeptide for Targeted Therapy of Non-Small-Cell Lung Cancer | ACS Applied Materials & Interfaces](https://pubs.acs.org/cms/10.1021/acsami.2c14570/asset/images/medium/am2c14570_0011.gif)